Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...